Analysis of microRNA expression profile induced by AICAR in mouse hepatocytes

Gene

Volumn 512, Issue 2, 2013, Pages 364-372

  Liu, Jia ^a   Liu, Wei ^b   Ying, Hao ^b   Zhao, Wei ^a   Zhang, Hong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

AMP activated protein kinase; Hepatocyte; Metabolism; MicroRNA

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MICRORNA;

ANIMAL CELL; ARTICLE; BIOINFORMATICS; CARCINOGENESIS; CELL METABOLISM; CONTROLLED STUDY; DIABETES MELLITUS; DOWN REGULATION; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GENOME ANALYSIS; GLUCONEOGENESIS; HEART FAILURE; HYPERTENSION; LIVER CELL; LIVER METABOLISM; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; OBESITY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS; SIGNAL TRANSDUCTION; UPREGULATION; WILD TYPE;

AMINOIMIDAZOLE CARBOXAMIDE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELLS, CULTURED; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEPATOCYTES; HYPOGLYCEMIC AGENTS; MALE; MICE; MICRORNAS; RIBONUCLEOTIDES; SIGNAL TRANSDUCTION;

MUS;

EID: 84870377279     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2012.09.118     Document Type: Article

References (53)

1. Alisi A., et al. Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab. Invest. 2011, 91:283-293.
2. Andreelli F., et al. Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology 2006, 147:2432-2441.
3. Ashburner M., et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 2000, 25:25-29.
4. Barroso E., et al. The PPARbeta/delta activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1alpha-Lipin 1-PPARalpha pathway leading to increased fatty acid oxidation. Endocrinology 2011, 152:1848-1859.
5. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
6. Bergeron R., et al. Effect of 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes 2001, 50:1076-1082.
7. Boominathan L. The guardians of the genome (p53, TA-p73, and TA-p63) are regulators of tumor suppressor miRNAs network. Cancer Metastasis Rev. 2010, 29:613-639.
8. Carissimi C., Fulci V., Macino G. MicroRNAs: novel regulators of immunity. Autoimmun. Rev. 2009, 8:520-524.
9. Carmona-Saez P., Chagoyen M., Tirado F., Carazo J.M., Pascual-Montano A. GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists. Genome Biol. 2007, 8:R3.
10. Cazanave S.C., et al. A role for miR-296 in the regulation of lipoapoptosis by targeting PUMA. J. Lipid Res. 2011, 52:1517-1525.
11. Chaveles I., et al. MicroRNA profiling in murine liver after partial hepatectomy. Int. J. Mol. Med. 2012, 29:747-755.
12. Cheung O., et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008, 48:1810-1820.
13. Corton J.M., Gillespie J.G., Hawley S.A., Hardie D.G. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?. Eur. J. Biochem. 1995, 229:558-565.
14. Elmen J., et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008, 452:896-899.
15. Esau C., et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 2006, 3:87-98.
16. Fabani M.M., Gait M.J. miR-122 targeting with LNA/2'-O-methyl oligonucleotide mixmers, peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA 2008, 14:336-346.
17. Foretz M., et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 2010, 120:2355-2369.
18. Furuta M., Kozaki K.I., Tanaka S., Arii S., Imoto I., Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010, 31:766-776.
19. Godlewski J., Bronisz A., Nowicki M.O., Chiocca E.A., Lawler S. microRNA-451: a conditional switch controlling glioma cell proliferation and migration. Cell Cycle 2010, 9:2742-2748.
20. Godlewski J., et al. MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol. Cell 2010, 37:620-632.
21. Grimson A., Farh K.K., Johnston W.K., Garrett-Engele P., Lim L.P., Bartel D.P. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 2007, 27:91-105.
22. He A., Zhu L., Gupta N., Chang Y., Fang F. Overexpression of micro ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin resistance in 3T3-L1 adipocytes. Mol. Endocrinol. 2007, 21:2785-2794.
23. Herrera B.M., et al. Global microRNA expression profiles in insulin target tissues in a spontaneous rat model of type 2 diabetes. Diabetologia 2010, 53:1099-1109.
24. Hochberg Y., Benjamini Y. More powerful procedures for multiple significance testing. Stat. Med. 1990, 9:811-818.
25. Holmes B.F., Kurth-Kraczek E.J., Winder W.W. Chronic activation of 5'-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J. Appl. Physiol. 1999, 87:1990-1995.
26. Ilan E., Tirosh O., Madar Z. Triacylglycerol-mediated oxidative stress inhibits nitric oxide production in rat isolated hepatocytes. J. Nutr. 2005, 135:2090-2095.
27. Iliopoulos D., Drosatos K., Hiyama Y., Goldberg I.J., Zannis V.I. MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism. J. Lipid Res. 2010, 51:1513-1523.
28. Jentzsch C., et al. A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J. Mol. Cell. Cardiol. 2012, 52:13-20.
29. Jin X., Ye Y.F., Chen S.H., Yu C.H., Liu J., Li Y.M. MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease. Dig. Liver Dis. 2009, 41:289-297.
30. John B., Enright A.J., Aravin A., Tuschl T., Sander C., Marks D.S. Human MicroRNA targets. PLoS Biol. 2004, 2:e363.
31. Johnnidis J.B., et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 2008, 451:1125-1129.
32. Kanehisa M., Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000, 28:27-30.
33. Khatri P., Draghici S., Ostermeier G., Krawetz S. Profiling gene expression using onto-express. Genomics 2002, 79:266-270.
34. Klipper-Aurbach Y., et al. Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. Med Hypotheses 1995, 45:486-490.
35. Koo S.H., et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 2005, 437:1109-1111.
36. Krutzfeldt J., et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438:685-689.
37. Lewis B.P., Shih I.H., Jones-Rhoades M.W., Bartel D.P., Burge C.B. Prediction of mammalian microRNA targets. Cell 2003, 115:787-798.
38. Liu Y., et al. Genomic analysis of miRNAs in an extreme mammalian hibernator, the Arctic ground squirrel. Physiol. Genomics 2010, 42A:39-51.
39. Luedde T. MicroRNA-151 and its hosting gene FAK (focal adhesion kinase) regulate tumor cell migration and spreading of hepatocellular carcinoma. Hepatology 2010, 52:1164-1166.
40. Mocellin S., Pasquali S., Pilati P. Oncomirs: from tumor biology to molecularly targeted anticancer strategies. Mini Rev. Med. Chem. 2009, 9:70-80.
41. Osborne J.D., et al. Annotating the human genome with Disease Ontology. BMC Genomics 2009, 10(Suppl. 1):S6.
42. Pencek R.R., et al. 5-Aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside causes acute hepatic insulin resistance in vivo. Diabetes 2005, 54:355-360.
43. Pold R., et al. Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes 2005, 54:928-934.
44. Reiter A.K., Bolster D.R., Crozier S.J., Kimball S.R., Jefferson L.S. Repression of protein synthesis and mTOR signaling in rat liver mediated by the AMPK activator aminoimidazole carboxamide ribonucleoside. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E980-E988.
45. Tang X., Muniappan L., Tang G., Ozcan S. Identification of glucose-regulated miRNAs from pancreatic beta cells reveals a role for miR-30d in insulin transcription. RNA 2009, 15:287-293.
46. Timmers S., et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011, 14:612-622.
47. Vázquez-Chantada M., et al. Evidence for LKB1/AMP-activated protein kinase/endothelial nitric oxide synthase cascade regulated by hepatocyte growth factor, S-adenosylmethionine, and nitric oxide in hepatocyte proliferation. Hepatology 2009, 49:608-617.
48. Viana A.Y., et al. Role of hepatic AMPK activation in glucose metabolism and dexamethasone-induced regulation of AMPK expression. Diabetes Res. Clin. Pract. 2006, 73:135-142.
49. Wang X.H., Qian R.Z., Zhang W., Chen S.F., Jin H.M., Hu R.M. MicroRNA-320 expression in myocardial microvascular endothelial cells and its relationship with insulin-like growth factor-1 in type 2 diabetic rats. Clin. Exp. Pharmacol. Physiol. 2009, 36:181-188.
50. Xu J., et al. MicroRNA-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting Wnt/beta-catenin pathway. Liver Int. 2012, 32:752-760.
51. Yamauchi T., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 2002, 8:1288-1295.
52. Yang J., Craddock L., Hong S., Liu Z.M. AMP-activated protein kinase suppresses LXR-dependent sterol regulatory element-binding protein-1c transcription in rat hepatoma McA-RH7777 cells. J. Cell. Biochem. 2009, 106:414-426.
53. Zhou G., et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001, 108:1167-1174.